Table 4.
Clinical and pathologic features stratified by nodal disease
| Characteristic | pN0 (N=49) | pN+ (N=9) | P |
|---|---|---|---|
| Age, years, mean (SD)a | 67.5 (9.9) | 71.1 (5.8) | 0.38 |
| Sex | |||
| Male | 16 (32.7) | 3 (33.3) | 1.00 |
| Female | 33 (67.3) | 6 (66.7) | |
| ECOG performance status | |||
| 0 | 40 (81.6) | 6 (66.7) | 0.35 |
| 1 or 2 | 8 (16.3) | 3 (33.3) | |
| Charlson comorbidity indexa, b | |||
| Median (IQR) | 0 (0–2) | 1 (0–3) | 0.46 |
| Smoking status | 1.00 | ||
| CS/FS | 40 (81.6) | 8 (88.9) | |
| NS | 9 (18.4) | 1 (11.1) | |
| Pack-yearsa | |||
| Median (IQR) | 35 (15–50) | 35 (11.25–55) | 0.63 |
| SUVmaxa | |||
| Median (IQR) | 2.8 (1.7–5.6) | 4.6 (2.6–5.4) | 0.16 |
| CT tumor diameter, cma | |||
| Median (IQR) | 1.4 (1.2–1.7) | 1.8 (1.3–1.9) | 0.13 |
| Consolidation-to-tumor ratioa | |||
| Median (IQR) | 0.89 (0.53–1.0) | 0.93 (1.0–1.0) | 0.09 |
| Histologic subtype | |||
| Adenocarcinoma | 42 (85.7) | 6 (66.7) | 0.1770 |
| Squamous cell/other | 7 (14.3) | 3 (33.3) | |
| Micropapillary and/or solid histologic component | |||
| Present (≥5%) | 20 (54.1) | 8 (100.0) | 0.0171 |
| Absent (<5%) | 17 (45.9) | 0 (0.0) | |
CS, current smoker; CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; FS, former smoker; IQR, interquartile range; NS, never smoker; SD, standard deviation; SUVmax, maximal standardized uptake value.
a
The Wilcoxon rank-sum test was used. For all other variables, Fisher’s exact test was used.
b
Charlson comorbidity index reported without age assessment.